Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China

Qianyun Liu,1,6 Qing Xiong,1,6 Fanghua Mei,1,6 Chengbao Ma,1 Zhen Zhang,1 Bing Hu,2 Junqiang Xu,2 Yongzhong Jiang,2 Faxian Zhan,2 Suhua Zhou,2 Li Tao,3 Xianying Chen,1 Ming Guo,1 Xin Wang,1 Yaohui Fang,4 Shu Shen,4 Yingle Liu,1 Fang Liu,1 Li Zhou,1 Ke Xu,1 Changwen Ke,5 Fei Deng,4 Kun Cai,2,* Huan Yan,1,* Yu Chen,1,* and Ke Lan1,*

*Correspondence: ckreal@163.com (K.C.); huanyan@whu.edu.cn (H.Y.); chenyu@whu.edu.cn (Y.C.); klan@whu.edu.cn (K.L.)
Received: September 2, 2021; Accepted: October 27, 2021; Published Online: November 3, 2021; https://doi.org/10.1016/j.xinn.2021.100181
© 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Graphical abstract

Public summary
- Sera from a large cohort of COVID-19 convalescents in Wuhan were collected for evaluation of anti-SARS-CoV-2 humoral immunity
- Anti-SARS-CoV-2 IgG was well maintained for 1 year in most convalescents and can potently neutralize the original strain and the B.1.1.7 variant
- Varying degrees of immune escape was observed on the tested variants, especially on B.1.351 and B.1.617.2 variants
- Sera from a few individuals showed remarkably broad neutralization potency against SARS-CoV-2 WT and variants
Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China

Qianyun Liu,1,6 Qing Xiong,1,6 Fanghua Mei,1,6 Chengbao Ma,1 Zhen Zhang,1 Bing Hu,2 Junqiang Xu,2 Yongzhong Jiang,2 Faxian Zhan,2 Suhua Zhou,2 Li Tao,2 Xiangying Chen,1 Ming Guo,1 Xin Wang,1 Yoahulu Fang,2 Shu Shen,2 Yingle Liu,1 Fang Liu,1 Li Zhou,1 Ke Xu,1 Changwen Ke,2 Fei Deng,3 Kun Cai,2,6 Huan Yan,1,6 and Ke Lan1,6

1State Key Laboratory of Virology, Institute for Vaccine Research and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China
2Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China
3Wuhan Jiang’an District Center for Disease Control and Prevention, Wuhan 430000, China
4National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
5Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
6These authors contributed equally

*Correspondence: ckreal@163.com (K.C.); huanyan@whu.edu.cn (H.Y.); chenyu@whu.edu.cn (Y.C.); klan@whu.edu.cn (K.L.)

Received: September 2, 2021; Accepted: October 27, 2021; Published Online: November 3, 2021; https://doi.org/10.1016/j.xinn.2021.100181
© 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Citation: Liu Q., Xiong Q., Mei F., et al., (2022). Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. The Innovation 3(1), 100181.

Most COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity, but it remains unclear how long it can maintain and how efficiently it can prevent the reemergence of the emerging SARS-CoV-2 variants. Here, we tested the sera from 248 COVID-19 convalescents around 1 year post-infection in Wuhan, the earliest known epicenter. SARS-CoV-2 immunoglobulin G (IgG) was well maintained in most patients and potently neutralizes the infection of the original strain and the B.1.1.7 variant. However, varying degrees of immune escape was observed on the other tested variants in a patient-specific manner, with individuals showing remarkably broad neutralization potency. The immune escape can be largely attributed to several critical spike mutations. These results suggest that SARS-CoV-2 can elicit long-lasting immunity but this is escaped by the emerging variants.

INTRODUCTION

SARS-CoV-2 emerged more than a year ago and rapidly swept across the world, developing into a long-lasting COVID-19 pandemic with devastating impacts.1-3 The situation has led to perpetual mutation of SARS-CoV-2, with numerous variants emerging around the world. In addition to the initial D614G mutation, the viral spike protein underwent antigenic drift and produced several variants of concern associated with local outbreaks, such as B.1.1.7 (alpha)4, B.1.351 (beta),5 P.1 (gamma, also known as B.1.1.28.1),6 B.1.525 (eta),7 B.1.617.2 (delta),8 and B.1.620, tested in this study.

Most COVID-19 patients can build anti-SARS-CoV-2 humoral immunity against SARS-CoV-2 after recovery.9,10 However, due to the lack of sufficient evidence about how long the protective immunity induced by prior infection or vaccination can maintain, the optimal interval between the vaccinations remains to be determined.11-13 In addition, increasing evidence showing these variants of concern, especially B.1.617.2 and B.1.351,14-20 remarkably increased resistance to the neutralizing antibodies, which is largely due to the mutations in the RBD region (ELISA) and pseudovirus neutralization assay demonstrated that the SARS-CoV-2-RBD-specific IgG antibodies remain detectable in most patients, which potently inhibits the infection of the SARS-CoV-2 pseudovirus (wild-type [WT]-D614G and B.1.1.7), but to a different extent was compromised in other tested variants (P.1, B.1.620, B.1.525, B.1.617.2, and especially B.1.351) and mutations (K417N, L452R, E484K, and E484Q/L452R). The decline of neutralizing activity was confirmed by authentic viral neutralization assays (WT, B.1.1.7, B.1.617.2, and B.1.351). Of note, we report eight individuals who developed relatively broad immunity against the tested variants, supporting the presence of broadly neutralizing epitopes. Overall, these results provided important implications for the control of the pandemic caused by the constantly emerging SARS-CoV-2 variants.

RESULTS

Durability and neutralizing activity

To evaluate the durability and neutralizing activity of SARS-CoV-2 antibodies after infection, we collected sera and clinical records from 248 COVID-19 patients infected around 1 year ago (11–12 months after symptom onset) in Wuhan. None of the convalescents had been administered with SARS-CoV-2 vaccine before sample collection according to the official record. Firstly, a rapid ELISA (colloidal gold) test for SARS-CoV-2-IgM/IgG antibody was applied. Seventy-nine percent (197/248) of the sera tested positive for anti-SARS-CoV-2-IgG, and 2.0% (5/248) tested positive for anti-SARS-CoV-2-IgM (Table S1). Conventional ELISA assays were then conducted to determine the anti-RBD-IgG level and the competitive ability of ACE2 to RBD binding of the sera. As we set OD490 of 0.31 (the mean OD490 value +3 SD of uninfected people's sera) as the cut-off value, 91% (225/248) tested positive for anti-SARS-CoV-2-RBD-IgG (Figure 1A). Our results also showed that the competitive ability is highly consistent with the anti-RBD-IgG level (Figures 1A–1E, Table S1), indicating that most RBD-targeting antibodies in the patients can interfere with the interaction between ACE2 and RBD. However, the anti-RBD IgG level and the neutralizing activity of the sera showed no statistically significant difference in patients with different severity (Figures 1A and 1B), gender (Figure 1C), and age (Figure 1E) except for the higher sera competitive ability of ACE2 to RBD binding was found in females (Figure 1D).

The neutralizing activities of the sera were tested with SARS-CoV-2 pseudovirus (WT-D614G) produced based on a replication-deficient VSV pseudotyping system (VSV-dG-Luc) and a BHK-21 cell line stably expressing hACE2 (BHK-21-hACE2). A total of 234 sera (94%) showed more than 50% neutralization when diluted 20-fold (NT50 > 20), and 195 samples (79%) showed 50% neutralization under 100-fold dilution (NT50 > 100). No statistically significant difference was observed between pseudovirus neutralizing activity and disease severity (Figure 1F). These results indicate that most patients could build and maintain an effective humoral immunity against SARS-CoV-2 for at least 1 year.

Cross-variant protection

Recently, SARS-CoV-2 variants with multiple mutations in spike protein have emerged in the United Kingdom (B.1.1.7), Brazil (P.1), Lithuania (B.1.620), Nigeria (B.1.525), South Africa (B.1.351), the United States (B.1.427/B.1.429),19,23 India (B.1.617.2), etc. We first tested the neutralizing activity of the top 180 potent sera in Figure 1F by the pseudoviruses of four variants, with the WT-D614G as a control (Figure 2A). When tested at 100-fold dilution, the mean neutralization efficiency of the sera against WT-D614G was 65%. However, the efficiency reduced to 59% for B.1.1.7, 48% for P.1, 47% for B.1.620, 43% for B.1.525, 39% for B.1.617.2, and 35% for B.1.351 (Figure 2B). Interestingly, we found that a small fraction of the patients showed cross-variant neutralizing activity. According to the reduction of neutralization to B.1.351, we selected eight representative sera (group 1, relatively resistant) from the 180 patients for further verification by NT50 determination, with another eight sera (group 2, relatively sensitive) for comparison. As expected, the sera in group 1 showed only a slight decrease in NT50 against the tested variants compared with WT-D614G (1.26- to 2.57-fold), while the sera in group 2 showed much higher sensitivity (1.83- to 8.10-fold). The NT50 data further confirmed that B.1.351 is the top immune escape variant.
among the tested strains, followed by B.1.617.2, B.1.525, B.1.620, P.1, and B.1.1.7, respectively (Figures 2C, 2D, and S1).

We further tested whether the immune escape of the tested variants is mainly attributed to the reduced neutralizing activity of SARS-CoV-2 RBD-specific antibodies. Five C57BL/6 mice were immunized three times with WT SARS-CoV-2 RBD human IgG-Fc recombinant protein. Seven weeks later, the mice sera were collected and tested using a pseudovirus neutralization assay. Similar to most of the convalescents’ sera, the sera from RBD protein-immunized mice showed reduced neutralization to P.1, B.1.525, B.1.617.2, and B.1.351, but not to B.1.1.7, which is reasonable as B.1.1.7 only has one mutation (N501Y) in the RBD region, a mutation without a prominent immune escape effect15,24,25 (Figure 2E). These results showed that the immune escape ability of the variants can be largely attributed to mutations in the RBD region.

To define the contribution of the critical mutations in the RBD region to immune escape, we produced pseudovirus bearing SARS-CoV-2 S protein (D614G) with K417N, L452R, E484K, and L452R/E484Q mutations, respectively. Notably, L452R and L452R/E484Q are two critical mutations in the B.1.427/B.1.429 (epsilon) and B.1.167.1 (kappa) variants, respectively. We tested the neutralizing activity of the 180 sera by these mutants with WT-D614G as a control. As shown in Figure 2F, when tested at 100-fold dilution, the mean neutralization efficiency of the sera against WT-D614G was 69%. However, the efficiency reduced to 61% for L452R, 55% for K417N, 54% for E484K, and 52% for L452R/E484Q. This result indicates that the RBD mutations are responsible for the reduction of cross-variant neutralization among the variants of concern.

Verification by authentic viruses

To confirm whether the neutralization results are consistent between the SARS-CoV-2 pseudovirus and the authentic virus, we first conducted the authentic SARS-CoV-2 virus (WT) neutralization assay to verify the 30 representative sera showing high, medium, and low neutralizing activities in Figure 1F, respectively. The SARS-CoV-2 nucleocapsid (N) protein immunofluorescence assay showed consistent results with the pseudovirus neutralization assay (Figure 3A).

We further verified the neutralizing activity of two groups of patients in Figures 2C and 2D (relatively resistant and relatively sensitive) by four authentic SARS-CoV-2 strains, including the WT strain and the B.1.1.7, B.1.617.2, and B.1.351 variant strains. The sera were diluted 100-fold, pre-incubated with these viruses, and then applied to Vero E6 cells for infection neutralization assay. As shown in Figure 3B, the neutralizing activity of the sera against the B.1.1.7 strain is similar to the WT strain but with a slight decrease. As for the B.1.617.2 and B.1.351 strains, the group 1 sera (relatively resistant) efficiently neutralized the infection of both the WT and the B.1.351 strains. In contrast, the group 2 sera (relatively sensitive) showed a remarkable reduction of neutralizing activity against the B.1.617.2 and the B.1.351 strains compared with the WT strain (Figure 3C). Again, these results are also consistent with the results from pseudovirus neutralization assays.
Previous studies show the protective immunity against seasonal coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1) may last only 6–12 months,26 and the titer of SARS-CoV-2 antibody has been reported to decline rapidly in the first several months,11 raising concerns about the durability of SARS-CoV-2 neutralizing antibodies elicited by either previous infection or vaccination. In addition, SARS-CoV-2 variants are constantly emerging during the COVID-19 pandemic, greatly challenging the development and application of effective neutralizing antibodies and vaccines.27,28 It is imperative to investigate the durability and breadth of the anti-SARS-CoV-2 humoral immunity. To this end, we collected convalescent sera in Wuhan in consideration of the several unique advantages over samples collected elsewhere: (1) Wuhan is the earliest reported epicenter of COVID-19 with most patients infected more than 1 year ago; (2) the patients were all infected by the original WT strain without the interference of potential multi-variant infections before sample collection;11 and (3) so far, most administered vaccines globally were designed based on the sequences of the original strain from Wuhan.

Firstly, we report that the effective neutralizing antibodies against SARS-CoV-2 could last at least 1 year in most COVID-19 convalescents without vaccination. Our results indicate that most people, including asymptomatic and elderly patients, could build and maintain effective anti-SARS-CoV-2 humoral immunity, with a few exceptions in each group for unknown reasons (Figure 1). We speculate that this phenotype might be attributed to the individual immune differences that deserve further study.

Another particular concern is the breadth of the anti-SARS-CoV-2 humoral immunity. Our study provides additional evidence that most sera collected from convalescents in Wuhan, even for 1 year post-infection, can still efficiently neutralize the infection of the B.1.1.7 variant. However, a significant decline of efficacy was observed on P.1, B.1.620, B.1.525, B.1.617.2, and B.1.351 (Figure 2B). B.1.351 displayed the most prominent immune escape ability among these tested variants, consistent with previous reports.15,16,29 Encouragingly, sera from a few individuals showed resistance to all tested variants (Figure 2C), indicating the presence of effective and broadly neutralizing antibodies. This brings hope for the identification of ideal broad neutralization epitopes essential for the development of antibody therapy and next-generation vaccines.

We next sought to characterize the critical factors that contribute to the immune escape. Based on previous studies and our neutralization results from RBD-vaccinated mouse sera, we focused on the four mutation sites in RBD of the tested variants in this study (Figure 2A). N501Y is the only mutation in B.1.1.7 RBDR, but this variant did not show remarkable immune escape in both our study (Figure 2E) and previous studies.30,31 Therefore, we tested several mutations in the other three critical sites, including K417N, L452R, E484K, and L452R/E484Q. The neutralization assay demonstrated that L452R/E484Q showed the strongest immune escape, followed by E484K, K417N, and L452R. The mean sera neutralization efficiency (Figures 2B and 2F) demonstrated that the critical RBD mutations play a major role in the immune escape of the variants. Importantly, the cross-variant protective sera from the group 1 convalescents can also tolerate these critical mutations (Figure 2F).

We do acknowledge some limitations of our studies. First, we did not determine the NT50 of all the sera because of the limitation of the sample volume, especially for those with lower neutralization activity. Secondly, we did not include all the possible mutations that can appear in other emerging variants. Thus, future studies could be done to investigate whether other mutations on spike proteins contribute in a leap of the immune escape of other variants.

To our knowledge, this study provides strong evidence that potent anti-SARS-CoV-2 humoral immunity can last for at least 1 year in most convalescents to protect them against the original virus (WT or WT-D614G), which means annual re-administration might be a feasible vaccination strategy to maintain anti-SARS-CoV-2 humoral immunity. However, convalescents and vaccinated people gradually lose protection against the constantly emerging immune escape variants. It remains to be determined whether re-administration of the variant-based or broadly neutralizing epitope-based vaccines can achieve effective cross-variant immunity. Overall, our study suggests that the timely update of vaccines rather than the durability of the SARS-CoV-2 humoral immunity should be more of our concern.

METHOD
Sample collection
COVID-19 convalescents from ten communities in five different streets (Chezhuan Street, Danshuichi Street, Huaqiao Street, Yiyuan Street, and Dazhi Street) in Jiang’an District in Wuhan, whose symptom onset was between January 1, 2020, and March 26, 2020, were randomly recruited to the cohort according to the criteria of the easy sampling principle. Convalescents who had mental disorders, dementia, difficulty in moving freely, or refused to enroll or were not contactable were excluded from the cohort. According to these sampling criteria, all 248 eligible individuals were recruited and their blood samples were collected from 19 January, 2021, to 26 January, 2021, and this collection was carried out through Hubei Provincial Centre For Disease Control and Prevention and Hubei Provincial Academy Of Preventive Medicine (HB CDC) with written consent under appropriate institutional review Boards approval (2021-012-01) and were deidentified. The recovery time, illness severity, gender, and age of donors were recorded (for extended data, see Table S1). Sera of the RBD-hFc vaccinated mice (three immunizations at days 0, 14, and 28, respectively) were collected 7 weeks after the last immunization from the suborbital venous plexus (WP20210007).

ELISA detection of SARS-CoV-2 S protein antibodies in the sera
The rapid IgG/IgM test was applied using the 2019-nCoV IgG/IgM detection kit (colloidal gold-based, Vazyme Biotech), which is based on the reactivity of IgG/IgM against SARS-CoV-2 S protein. The anti-RBD IgG level in sera was tested using the SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Titer Assay Kit (Sino Biological), which is based on the reactivity of IgG against SARS-CoV-2 RBD. The competitive ability of ACE2 to RBD binding of sera was tested through SARS-CoV-2 Neutralizing Antibodies Test Kit (ELISA, Wuxi BioHermes Bio & Medical Technology), which is based on the competition between the neutralizing antibodies in sera and ACE2 to horse-radish peroxidase-labeled RBD protein (HRP-RBD). These ELISA detection tests were applied following the manufacturer’s instructions.

Cell culture
HEK293T (ATCC, CRL-1168), BHK-21 (ATCC, CCL-10), and Vero E6 cells (ATCC, CRL-1586) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) ( Gibco) supplemented with 10% fetal bovine serum (FBS), 2.0 mM L-glutamine, 110 mg/L sodium pyruvate, and 4.5 g/L D-glucose. BHK-21 ACE2 (clone 7), which stably expresses human ACE2 was generated based on BHK-21 through lentiviral transduction and maintained with puromycin at 1 µg/mL. 1L-Hybridioma (CRL-2700) secreting a monoclonal antibody targeting VSV glycoprotein was cultured in minimum essential medium with Earle’s salts and 2.0 mM L-glutamine (MEM, Gibco) supplemented with 10% FBS. All cells were cultured at 37°C in 5% CO2 with regular passage every 2–3 days.

Plasmids and protein
The DNA sequences of human codon-optimized S proteins from SARS-CoV-2 variants (B.1.1.7, GISAID: EPI-ISL-601443; B.1.351, GISAID: EPI-ISL-998517; B.1.526, GISAID: EPI-ISL-998487; B.1.526, GISAID: EPI-ISL-2378732; B.1.526, GISAID: EPI-ISL-1093472; B.1.620, GISAID: EPI-ISL-1616662) and S protein mutations were commercially synthesized or generated by overlapping PCR-based mutagenesis using pCAGGS/SARS-CoV-2-2S-C9 (a gift from Dr. Weihui Li, National Institute of Biological Science, Beijing, China) as the template and cloned into pCAGGS vector with C-terminal 18 amino acid (aa) truncation to improve VSV pseudotyping efficiency.12 The plasmid pCAGGS/SARS-CoV-2-RBD-hFc was constructed by inserting the RBD sequence (aa. 331–525) into the pCAGGS vector for the expression of RBD.
The SARS-CoV-2 pseudovirus packaging with spike proteins from the WT SARS-CoV-2 and the SARS-CoV-2 variants were produced according to a published protocol with minor modifications. In brief, Vero-E6 cells were transfected with plasmids expressing different S proteins through lipofectamine 2000 (BioSharp, China). After 24 h, the transfected cells were inoculated with VSV-d-gLuc (1 x 10^5 TCID₅₀/mL) diluted in DMEM for 5 h at 37°C and then replenished with growth medium (DMEM with 10% FBS) containing anti-VSV-G monoclonal antibody (1:100, cultured supernatant, 1:20). Twenty-four hours later, the SARS-CoV-2 pseudovirus-containing supernatant was harvested and clarified for 3,000 rpm for 10 min, aliquoted, and frozen at −80°C for storage. The TCID₅₀ of the pseudovirus was determined using a serial dilution-based infection assay on BHK-21-hACE2 cells and calculated according to the Reed-Muench method.

SARS-CoV-2 pseudovirus neutralization assay

The SARS-CoV-2 pseudoviruses (3 x 10^5 TCID₅₀/well) were incubated with serial-diluted sera at room temperature for 30 min in 96-well white flat-bottom culture plates and then mixed with trypsinized BHK-21-hACE2 cells at a density of 2 x 10⁴/well. After 16 h, the medium of the infected cells was removed, and the cells were lysed with 1 x Bright-Glo Luciferase Assay reagent (Promega) for chemiluminescence detection using a SpectraMax iD3 multi-well luminometer (Molecular devices). The 50% neutralization dilution titer (NT₅₀) was calculated by GraphPad Prism 7 software with nonlinear regression curve fitting (normalized response, variable slope).

Authentic SARS-CoV-2 neutralization assay

The SARS-CoV-2 WT strain (ICVAS 6.7512) and B.1.351 strain (NPRC 2.062100001) were provided by the National Virus Resource, Wuhan Institute of Virology, Chinese Academy of Sciences, the SARS-CoV-2 B.1.1.7 strain (240108) and B.1.617.2 strain (YJ20210707-01) was provided by Hubei Provincial Centre for Disease Control and Prevention. All SARS-CoV-2 authentic virus-related experiments (S01320101A) were approved by the Biosafety Committee Level 3 (ABSL-3) of Wuhan University, Wuhan Institute of Virology and Hubei Provincial Centre for Disease Control and Prevention. In brief, sera were serially diluted in culture medium and mixed with 200 TCID₅₀ SARS-CoV-2 for 30 min at room temperature. The mixture was then added to Vero E6 cells in 96-well plates and incubated for 24 h, and the cells were fixed with 4% paraformaldehyde in PBS at room temperature for 1 h, permeabilized with 0.2% Triton X-100 for 10 min, and then blocked with 1% BSA/PBS at 37°C for 1 h. Cells were subsequently incubated with a mouse monoclonal antibody targeting SARS-CoV/SARS-CoV-2 nucleocapsid (40143-MM05, Sino Biological) at 1:500 dilution and 37°C for 1 h, and then incubated with 2 μg/mL of Alexa Fluor 594-conjugated goat anti-mouse IgG antibody (A-11032, Thesiso Foodier Scientific) at 37°C for 1 h. The nucleus was stained with Hoechst 33342. Images were acquired with an inverted fluorescence microscope (DMI8, Leica).

Statistical analysis

Data are presented as mean values with SEM or SD. All statistical analyses were done using GraphPad Prism 7. Differences between two independent samples were evaluated by two-tailed Mann-Whitney U tests, and p < 0.05 was considered statistically significant. Differences between two related samples were evaluated by paired two-tailed t-tests.

REFERENCES

1. Zhou, P., Yang, XL., Wang, X.G., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273.
2. Grubaugh, N.D., Hodcroft, E.B., Fauver, J.R., et al. (2021). Public health actions to control new SARS-CoV-2 variants. Cell 184, 1127–1132.
3. Chen, L., Liu, W., Zhang, G., et al. (2020). RNA based nNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerging Infectious Diseases 9, 313–319.
4. Public Health England (2020). Investigation of Novel SARS-CoV-2 Variant: Variant of Concern 202012/01, Technical Briefing 5.
5. Tegally, H., Wilkinson, E., Giovanetti, M., et al. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. https://doi.org/10.1101/2020.12.21.20266400.
6. Faria, N.R., Claro, I.M., Candido, D., et al. (2021). Genomic characterisation of an emerging SARS-CoV-2 lineage in Manaus: preliminary findings. Virology 532, 815–821.
7. Ozer, E.A., Simons, L.M., Adewumi, O.M., et al. (2021). High prevalence of SARS-CoV-2 B.1.1.7 (UK variant) and the novel B.1.5.2.5 lineage in Oyo State, Nigeria. medRxiv. https://doi.org/10.1101/2021.04.09.21235208.
8. Yadav, P.D., Nyayanit, D.A., Sahay, R.R., et al. (2021). Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India. Virology 202102107-01. The B.1.1.7 lineage. J. Trav. Med. 28, ta009.
9. Ni, L., Ye, F., Cheng, M.L., et al. (2020). Detection of SARS-CoV-2 S variant in human specimen. Nature 586, 276–280.
10. Wang, P., Nair, M.S., Liu, L., et al. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135.
11. Hofmann, M., Arora, P., Gross, R., et al. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393.e12.
12. Wang, R., Zhang, Q., Ge, J., et al. (2021). Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. https://doi.org/10.1016/j.immuni.2021.06.003.
13. Planas, D., Veyer, D., Baidaulk, A., et al. (2021). Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature 596, 276–280.
14. Planas, D., Veyer, D., Baidaulk, A., et al. (2021). Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature 596, 276–280.
15. Wang, P., Nair, M.S., Liu, L., et al. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135.
16. Hoffmann, M., Arora, P., Gross, R., et al. (2021). SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393.e12.
17. Wang, R., Zhang, Q., Ge, J., et al. (2021). Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. https://doi.org/10.1016/j.immuni.2021.06.003.
18. Planas, D., Veyer, D., Baidaulk, A., et al. (2021). Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature 596, 276–280.
31. Xie, X., Liu, Y., Liu, J., et al. (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620–621.
32. Schwegmann-Wessels, C., Glende, J., Ren, X., et al. (2009). Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus. J. Gen. Virol. 90, 1724–1729.
33. Nie, J., Li, O., Wu, J., et al. (2020). Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699–3715.
34. Matumoto, M. (1949). A note on some points of calculation method of LD50 by Reed and Muench. Jpn. J. Exp. Med. 20, 175–179.
35. Fengjuan, C., Bosheng, L., Peter, H., et al. (2021). A case of new variant COVID-19 first emerging in South Africa detected in airplane pilot—Guangdong province, China, January 6, 2021. China CDC Weekly 3, 28–29.

ACKNOWLEDGMENTS
This study was supported by grants from the National Science and Technology Major Project (2018YFA0900801), China NSFC projects (32041007, 32070160, and 82041004), Fundamental Research Funds for the Central Universities (20420 21kf0220 and 2042020k0024), the Advanced Customer Cultivation Project of Wuhan National Biosafety Laboratory (2021ACCP-MS10) and Special Fund for COVID-19 Research of Wuhan University. We are grateful to Beijing Taikang Yicai Foundation for their great support to this work.

AUTHOR CONTRIBUTIONS
K.L., Y.C., H.Y., and K.C. conceptualized the study design. F.H.M., F.X.Z., X.Y.C., B.H., J.Q.X., Y.Z.J., S.H.Z., and L.T. collected the samples. Q.Y.L., Q.X., F.H.M., C.B.M., Z.Z., X.Y.C., M.G., X.W., Y.H.F., S.S., and C.W.K. did the laboratory tests. Q.Y.L., Q.X., F.H.M., Y.L.L., F.L., L.Z., K.X., C.W.K., F.D., H.Y., and Y.C. analyzed the data. Q.Y.L., O.X., F.H.M., H.Y., Y.C., and K.L. interpreted the results. Q.Y.L., Q.X., F.H.M., H.Y., and Y.C. wrote the initial drafts of the manuscript. Q.Y.L., K.C., H.Y., Y.C., and K.L. revised the manuscript. Y.L.L., F.L., L.Z., K.X., C.W.K., J.Q.X., Y.Z.J., and F.D. commented on the manuscript. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.xinn.2021.100181.

LEAD CONTACT WEBSITE
http://www.bio.whu.edu.cn/info/1191/4268.htm.
http://www.bio.whu.edu.cn/info/1191/4264.htm.
http://www.bio.whu.edu.cn/info/1191/5432.htm.